Table 2.

Effect of Apigenin Treatment on OVA-Induced Alterations in Serum Histamine, OVA-Specific IgE, Total IgE and IgG1, and β-Hexosaminidase Levels in AR Mice.^a

Parameters	Treatment
	Normal	AR Control	MLT (10)	AP (5)	AP (10)	AP (20)	Per se
Histamine (µg/mL)	70.94 ± 8.47	368.40 ± 5.27b	100.20 ± 10.02c,d	340.80 ± 11.10	248.60 ± 7.56c,d	136.80 ± 8.63c,d	82.41 ± 10.23
OVA-specific IgE (ng/mL)	12.69 ± 2.16	61.75 ± 1.62b	21.54 ± 1.03c,d	59.35 ± 2.38	43.99 ± 2.14c,d	28.18 ± 2.22c,d	14.75 ± 1.72
Total IgE (ng/mL)	92.78 ± 12.82	442.50 ± 13.13b	148.60 ± 16.45c,d	401.00 ± 10.24	324.70 ± 11.77c,d	185.80 ± 13.92c,d	121.70 ± 13.77
Total IgG1 level (ng/mL)	0.26 ± 0.06	0.72 ± 0.05b	0.41 ± 0.05c,d	0.68 ± 0.05	0.65 ± 0.03	0.49 ± 0.06c,d	0.39 ± 0.05
β-hexosaminidase (ng/mL)	13.28 ± 1.60	44.43 ± 1.75b	18.88 ± 1.71c,d	42.32 ± 1.41	33.10 ± 1.48c,d	26.21 ± 1.69c,d	19.08 ± 1.58

Abbreviations: ANOVA, analysis of variance; AP (5), apigenin (5 mg/kg) treated; AP (10), apigenin (10 mg/kg) treated; AP (20), apigenin (20 mg/kg) treated; AR, allergic rhinitis; Ig, immunoglobulin; MLT (10), montelukast (10 mg/kg) treated; OVA, ovalbumin; SEM, standard error of the mean.

^a Data are represented as mean ± SEM (n = 4-6) and analyzed by one-way ANOVA followed by Tukey multiple range test. Figures in parentheses indicate dose in mg/kg.

^b P < .05 as compared with normal group.

^c P < .05 as compared with AR control group.

^d P < .05 as compared montelukast with apigenin.